home / stock / tsvt / tsvt news


TSVT News and Press, 2seventy bio Inc. From 03/01/23

Stock Information

Company Name: 2seventy bio Inc.
Stock Symbol: TSVT
Market: NASDAQ
Website: 2seventybio.com

Menu

TSVT TSVT Quote TSVT Short TSVT News TSVT Articles TSVT Message Board
Get TSVT Alerts

News, Short Squeeze, Breakout and More Instantly...

TSVT - Rivian Automotive, First Horizon, iQIYI among premarket losers' pack

Performance Shipping ( PSHG ) -43% . Novavax ( NVAX ) -28% on Q4 earnings release . Tupperware Brands TUP -25% after posting preliminary results . First Horizon ( FHN ) -23% as TD says it won't receive regulatory OK in time for May close . M...

TSVT - 2seventy bio prices $125M in upsized stock offering

2seventy bio ( NASDAQ: TSVT ) priced its follow on underwritten public offering of 10.87M shares at a public offering price of $11.50/share. Underwriters granted 30-day option to purchase up to an additional 1.63M shares. Gross proceeds are expected to be ~$125M, ...

TSVT - 2seventy bio Announces Pricing of Upsized Public Offering of Common Stock

2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of it...

TSVT - 2seventy bio launches $100M stock offering

2seventy bio ( NASDAQ: TSVT ) on Tuesday announced an underwritten public offering of $100 million of shares of its common stock. All of the shares in the proposed offering are being offered by 2seventy bio. 2seventy bio said it intends to grant the underwriters a 30-day option to...

TSVT - 2seventy bio Announces Proposed Public Offering of Common Stock

2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today that it has commenced an underwritten public offering of $100 million of shares of...

TSVT - What To Expect From Bristol-Myers Squibb In 2023

Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...

TSVT - Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study

Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and predictable safety profile of Abecma Abecma is the first...

TSVT - 2seventy bio (TSVT) Investor Presentation - Slideshow

The following slide deck was published by 2seventy bio, Inc. in conjunction with this event. For further details see: 2seventy bio (TSVT) Investor Presentation - Slideshow

TSVT - Stocks To Watch: Spotlight On Google, Disney, Regeneron Pharmaceuticals And Hesai Group IPO

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

TSVT - Medigene Receives $3 Million Milestone Payment from 2seventy bio

Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW Therapeutics Payment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried ...

Previous 10 Next 10